Business Context and Reporting Period
This Form 8-K Current Report was filed by cbdMD, Inc. on January 9, 2020. The filing discloses the entry into a material definitive agreement regarding a firm commitment underwritten public offering of common stock. The Company is an emerging growth company incorporated in North Carolina.
Key Financial Metrics and Transaction Details
- Offering Size: 16,000,000 shares of Common Stock at an offering price of $1.00 per share.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to an additional 2,400,000 shares.
- Expected Net Proceeds: Approximately $14.6 million (excluding the over-allotment option) after deducting underwriting discounts, commissions, and estimated expenses.
- Underwriting Compensation: 7.5% of gross cash proceeds in discounts and commissions.
- Representative's Warrant: Issuance of a warrant to purchase 480,000 shares (3% of shares sold) exercisable at $1.25 per share.
- Estimated Expenses: Approximately $230,000 payable by the Company, excluding underwriting fees.
- Use of Proceeds: General working capital purposes.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with ThinkEquity (a division of Fordham Financial Management, Inc.) as the representative and The Benchmark Company, LLC as co-manager. The transaction is expected to close on January 14, 2020, subject to customary conditions.
Additionally, eight executive officers and directors have indicated a non-binding interest in purchasing up to 455,000 shares in the offering. Executives, directors, and 5% or greater shareholders have entered into 45-day Lock-Up Agreements restricting the sale of their existing shares.
Outlook, Risks, and Contingencies
- Forward-Looking Statements: The filing contains forward-looking statements regarding expected net proceeds, which are subject to risks and uncertainties detailed in the Company's other SEC filings.
- Indications of Interest: The purchase of shares by executive officers and directors is not binding; the underwriters may sell more, less, or no shares to them.
- Legal Disclosures: Representations and warranties in the Underwriting Agreement were made solely for the benefit of the parties to the agreement and may not reflect facts applicable to investors.
Key Facts for Investor Verification
- Verify the final closing date of the offering (expected January 14, 2020) and whether the over-allotment option was exercised.
- Confirm the actual net proceeds received versus the estimated $14.6 million.
- Review the Company's most recent 10-K or 10-Q for historical financial performance, as this 8-K does not contain operational financial data.
- Monitor the impact of the 45-day lock-up agreements on future share liquidity.
- Check for any subsequent filings regarding the utilization of proceeds for working capital.